These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 16553532)

  • 1. Long-term sertraline treatment of children and adolescents with major depressive disorder.
    Rynn M; Wagner KD; Donnelly C; Ambrosini P; Wohlberg CJ; Landau P; Yang R
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):103-16. PubMed ID: 16553532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials.
    Wagner KD; Ambrosini P; Rynn M; Wohlberg C; Yang R; Greenbaum MS; Childress A; Donnelly C; Deas D;
    JAMA; 2003 Aug; 290(8):1033-41. PubMed ID: 12941675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.
    Atkinson S; Lubaczewski S; Ramaker S; England RD; Wajsbrot DB; Abbas R; Findling RL
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):55-65. PubMed ID: 29185786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents.
    Alderman J; Wolkow R; Fogel IM
    J Child Adolesc Psychopharmacol; 2006; 16(1-2):117-29. PubMed ID: 16553533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.
    McNamara RK; Strawn JR; Tallman MJ; Welge JA; Patino LR; Blom TJ; DelBello MP
    J Child Adolesc Psychopharmacol; 2020 Jun; 30(5):293-305. PubMed ID: 32167792
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    ; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder.
    Koran LM; Hackett E; Rubin A; Wolkow R; Robinson D
    Am J Psychiatry; 2002 Jan; 159(1):88-95. PubMed ID: 11772695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Duloxetine in Children and Adolescents with Major Depressive Disorder in Japan: A Randomized Double-Blind Placebo-Controlled Clinical Trial Followed by an Open-Label Long-Term Extension Trial.
    Saito T; Ishida M; Nishiyori A; Ochiai T; Katagiri H; Matsumoto H
    J Child Adolesc Psychopharmacol; 2022 Apr; 32(3):132-142. PubMed ID: 35319270
    [No Abstract]   [Full Text] [Related]  

  • 11. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder.
    Rynn MA; Siqueland L; Rickels K
    Am J Psychiatry; 2001 Dec; 158(12):2008-14. PubMed ID: 11729017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials.
    Atkinson S; Thurman L; Ramaker S; Buckley G; Jones SR; England R; Wajsbrot D
    CNS Spectr; 2019 Oct; 24(5):496-506. PubMed ID: 30419989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.
    Arango C; Buitelaar JK; Fegert JM; Olivier V; Pénélaud PF; Marx U; Chimits D; Falissard B;
    Lancet Psychiatry; 2022 Feb; 9(2):113-124. PubMed ID: 34919834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.
    DelBello MP; Hochadel TJ; Portland KB; Azzaro AJ; Katic A; Khan A; Emslie G
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):311-7. PubMed ID: 24955812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial.
    Robb AS; Cueva JE; Sporn J; Yang R; Vanderburg DG
    J Child Adolesc Psychopharmacol; 2010 Dec; 20(6):463-71. PubMed ID: 21186964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance study for adolescent depression.
    Cheung A; Kusumakar V; Kutcher S; Dubo E; Garland J; Weiss M; Kiss A; Levitt A
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):389-94. PubMed ID: 18759650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.